23-Valent Pneumococcal Polysaccharide Vaccination Does Not Prevent Community-Acquired Pneumonia Hospitalizations Due to Vaccine-Type <i>Streptococcus pneumoniae</i>

23-Valent Pneumococcal Polysaccharide Vaccination Does Not Prevent Community-Acquired Pneumonia Hospitalizations Due to Vaccine-Type <i>Streptococcus pneumoniae</i>

Controversy exists regarding the clinical effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) for the prevention of serotype-specific community-acquired pneumonia (CAP). The objective of this study was to define the effectiveness of PPSV23 for the prevention of CAP hospitaliz...

Full description

Bibliographic Details
Main Authors: Thomas Chandler, Stephen Furmanek, Ruth Carrico, Dawn Balcom, Forest Arnold, Julio Ramirez
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Microorganisms
Subjects:
community-acquired pneumonia
pneumococcal pneumonia
pneumococcal vaccine
polysaccharide vaccine
Online Access:https://www.mdpi.com/2076-2607/10/3/560

Internet

https://www.mdpi.com/2076-2607/10/3/560

Similar Items